

NORWOOD IMMUNOLOGY STEM CELL DEVELOPMENTS

Medical technologies group Norwood Abbey Ltd [ASX:NAL] advises that Norwood Immunology Ltd, in which Norwood Abbey Ltd has a 21% shareholding, has announced an updated strategy with a particular focus on:

- Provisions of stem cell services and therapies, and
- Licensing and partnerships re intellectual property and therapies based on stem cells, the immune system and immune cell targeting of vaccines.

Norwood Immunology Ltd (“NIM”) states that it aims to “substantially increase the value of the Company ... via possible development and provision of both veterinary and human stem cell banking and processing services, as well as possible provision of veterinary and human stem cell (and immunology based) clinical therapies”.

NIM has under consideration “the in-licensing or acquisition of revenue-producing stem cell technologies”. “NIM expects to begin earning its first stem cell revenues in 2008/2009, with the expectation of progressively increasing revenues from the possible provision of stem processing and banking (veterinary and/or human) from 2009 onwards.

Full details of the NIM Strategic Overview have been posted on the NIM website at www.norwoodimmunology.com including explanations and information in relation to the nature and application of stem cell technologies.

To find out more about the Norwood group, visit www.norwoodabbey.com

For further information please contact:

Norwood Abbey Ltd
+61-3-9770-0063